Wall Street equity research analysts covering AVITA Medical maintain a consensus twelve-month price target that generally hovers around $8.00 to $10.20 per share. Analyst ratings lean predominantly toward buy and moderate hold recommendations, reflecting optimism regarding the long-term market adoption of its regenerative skin-restoration platform and expanding label indications. However, individual forecasts vary depending on short-term quarterly revenue growth rates, expense management, and broader macroeconomic sentiment affecting small-cap medical device stocks.